TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares From 10/27/23

2023-10-27 16:13:47 ET Summary Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved for multiple GI indications. Ironwood recently a...

2023-10-27 02:23:19 ET ETFs: ( EWA ), ( FXA ), ( FLAU ). Currency: ( USD:AUD ) More on Australia economy: Australia's services sector rises to 51.8; composite PMI 4-month high in September RBA keeps interest rate on hold at 4.10% in ...

2023-10-27 02:02:10 ET Takeda Pharmaceutical Company Limited (TAK) Q2 2023 Earnings Conference Call October 26, 2023 6:00 AM ET Company Participants Christopher O'Reilly - Head of Investor Relations Christophe Weber - President and Chief Executive Officer Andy Pl...

CenterPoint Energy Inc (Holding Co) (CNP) is expected to report $0.37 for Q3 2023 The Hershey Company (HSY) is expected to report $2.47 for Q3 2023 ASE Technology Holding Co. Ltd. American Depositary Shares (each representing Two) (ASX) is expected to report for Q3 2023 Reliance Steel...

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of) (TAK) is expected to report for Q2 2024

2023-10-26 02:26:28 ET More on Takeda Pharmaceutical Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade) Takeda fails in second Phase 3 trial for CPF therapy Alofisel Taked...

Revenue Growth of +6.4% at Actual Exchange Rate (AER); +1.4% Growth at Constant Exchange Rate (CER), Driven by Growth & Launch Products (+13% at CER) Core Operating Profit Year-on-Year Change of -9.5% at CER Reflecting Generic Impact, Lower Demand for Coronavirus Vaccines and Incr...

2023-10-24 14:43:31 ET Summary High yields may seem attractive, however, homework can go a long way. Takeda's Phase 3 ADMIRE CD II study & Phase 3 EXCLAIM-2 trial both failed to meet key endpoints, thus impacting the company's FY23 outlook. When the company reports Q2 earn...

2023-10-23 06:09:11 ET Summary Daiichi Sankyo is a Japanese pharmaceutical company known for its flagship products Lixiana and Enhertu. Enhertu is becoming a popular treatment for breast cancer, based on technology that is substituting chemotherapy. Long-term earnings outlook ...

2023-10-19 18:23:58 ET Summary Hutchmed's 2023 interim financial report shows progress towards profitability, with revenue from product sales and R&D services increasing. The company has a strong balance sheet with $856 million in cash and a low level of bank borrowings. T...